Cargando…
Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test
The genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) differs from that of the primary tumor and is dynamic during tumor progression. The real-time and repeated characterization of this process via conventional solid tumor biopsies is challenging. Alternatively, circulatin...
Autores principales: | González-Billalabeitia, Enrique, Conteduca, Vincenza, Wetterskog, Daniel, Jayaram, Anuradha, Attard, Gerhardt |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398580/ https://www.ncbi.nlm.nih.gov/pubmed/30413805 http://dx.doi.org/10.1038/s41391-018-0098-x |
Ejemplares similares
-
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2020) -
Identification of single nucleotide variants using position-specific error estimation in deep sequencing data
por: Kleftogiannis, Dimitrios, et al.
Publicado: (2019) -
Genome-wide plasma DNA methylation features of metastatic prostate cancer
por: Wu, Anjui, et al.
Publicado: (2020) -
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018) -
Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges
por: Trujillo, Blanca, et al.
Publicado: (2022)